These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12804052)

  • 21. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
    Conti PS
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
    Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
    Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
    J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
    Hoffmann M; Troch M; Eidherr H; Traub-Weidinger T; Jonak C; Muellauer L; Raderer M
    Leuk Lymphoma; 2011 Jan; 52(1):42-5. PubMed ID: 21133720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report.
    Papajik T; Prochazka V; Raida L; Kubova Z; Myslivecek M; Drymlova J; Buriankova E; Kucerova L; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):109-12. PubMed ID: 17690751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Spies SM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):10-3. PubMed ID: 14762739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Gordon LI
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
    J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
    Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
    Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
    Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP; Singla S; Thakral P; Ballal S; Bal C
    Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.